Vernon T. Phan

1.5k total citations
16 papers, 875 citations indexed

About

Vernon T. Phan is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Vernon T. Phan has authored 16 papers receiving a total of 875 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 5 papers in Hematology and 3 papers in Oncology. Recurrent topics in Vernon T. Phan's work include Retinoids in leukemia and cellular processes (6 papers), Acute Myeloid Leukemia Research (5 papers) and Protein Kinase Regulation and GTPase Signaling (2 papers). Vernon T. Phan is often cited by papers focused on Retinoids in leukemia and cellular processes (6 papers), Acute Myeloid Leukemia Research (5 papers) and Protein Kinase Regulation and GTPase Signaling (2 papers). Vernon T. Phan collaborates with scholars based in United States, United Kingdom and Australia. Vernon T. Phan's co-authors include Frank McCormick, Abigail L. Miller, Jesse Lyons, Amy Young, Scott C. Kogan, Michelle M. Le Beau, Jastinder Sohal, Guanglei Zhuang, Xiumin Wu and Napoleone Ferrara and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Vernon T. Phan

16 papers receiving 863 citations

Peers

Countries citing papers authored by Vernon T. Phan

Since Specialization

Citations

This map shows the geographic impact of Vernon T. Phan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vernon T. Phan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vernon T. Phan more than expected).

Fields of papers citing papers by Vernon T. Phan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vernon T. Phan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vernon T. Phan. The network helps show where Vernon T. Phan may publish in the future.

Co-authorship network of co-authors of Vernon T. Phan

This figure shows the co-authorship network connecting the top 25 collaborators of Vernon T. Phan. A scholar is included among the top collaborators of Vernon T. Phan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vernon T. Phan. Vernon T. Phan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Novel small molecules induced ROS accumulation and antitumor activity based on an oxidative stress gene signature. 2018 ·Journal of Clinical Oncology ·Andrew A. Protter, Vernon T. Phan, (unknown), Kevin Kim, (unknown), Sidney P. Elmer, Damir Herman, Johan A. Grahnen, Pek Yee Lum	2
2	The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance 2017 ·Molecular Cancer Therapeutics ·Eleni Venetsanakos, Ken A. Brameld, Vernon T. Phan, Erik Verner, Timothy D. Owens, Yan Xing, Danny Tam, Jacob LaStant, (unknown), Dane E. Karr, Ronald J. Hill, Mary E. Gerritsen, David Goldstein, Jens Oliver Funk, J. Michael Bradshaw	22
3	Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors 2017 ·Journal of Medicinal Chemistry ·Ken A. Brameld, Timothy D. Owens, Erik Verner, Eleni Venetsanakos, J. Michael Bradshaw, Vernon T. Phan, Danny Tam, (unknown), Jin Shu, Jacob LaStant, David G. Loughhead, (unknown), Dane E. Karr, Mary E. Gerritsen, David Goldstein, Jens Oliver Funk	84
4	Androgen Receptor Immunohistochemistry as a Companion Diagnostic Approach to Predict Clinical Response to Enzalutamide in Triple-Negative Breast Cancer 2017 ·JCO Precision Oncology ·Varun Kumar, Jianjun Yu, Vernon T. Phan, Iulia Cristina Tudor, Amy Peterson, Hirdesh Uppal	22
5	Cooperative Dynamics of AR and ER Activity in Breast Cancer 2016 ·Molecular Cancer Research ·Nicholas C. D’Amato, Melita A. Gordon, Beatrice Babbs, Nicole S. Spoelstra, Kiel T. Carson Butterfield, Kathleen C. Torkko, Vernon T. Phan, Valerie N. Barton, Thomas J. Rogers, Carol A. Sartorius, Anthony Elias, Jason Gertz, Britta M. Jacobsen, Jennifer K. Richer	105
6	Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF–induced neutrophil recruitment 2013 ·Proceedings of the National Academy of Sciences ·Vernon T. Phan, Xiumin Wu, Jason Cheng, (unknown), Alicia S. Chung, Guanglei Zhuang, Christopher Tran, Qinghua Song, Marcin Kowanetz, Amy Sambrone, (unknown), Y. Gloria Meng, Erica L. Jackson, Franklin Peale, Melissa R. Junttila, Napoleone Ferrara	93
7	Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy 2011 ·Proceedings of the National Academy of Sciences ·Jenny Yao, Xiumin Wu, Guanglei Zhuang, Ian Kasman, (unknown), Vernon T. Phan, Masabumi Shibuya, Napoleone Ferrara, Carlos Bais	81
8	The RasGAP Proteins Ira2 and Neurofibromin Are Negatively Regulated by Gpb1 in Yeast and ETEA in Humans 2010 ·Molecular and Cellular Biology ·Vernon T. Phan, Vivianne W. Ding, Fenglei Li, Robert J. Chalkley, Alma L. Burlingame, Frank McCormick	45
9	Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia 2010 ·The Journal of Experimental Medicine ·Letetia C. Jones, Guangwei Wei, Sabina Ševčı́ková, Vernon T. Phan, Sachi Jain, (unknown), Jasmine C. Wong, Min Li, (unknown), (unknown), (unknown), (unknown), Thelma R. Tennant, Kevin Shannon, Scott W. Lowe, Michelle M. Le Beau, Scott C. Kogan	52
10	Chapter 1 Ras Signaling and Therapies 2009 ·Advances in cancer research ·Amy Young, Jesse Lyons, Abigail L. Miller, Vernon T. Phan, (unknown), Frank McCormick	166
11	Forced retinoic acid receptor α homodimers prime mice for APL-like leukemia 2006 ·Cancer Cell ·Thomas Sternsdorf, Vernon T. Phan, (unknown), (unknown), Jastinder Sohal, (unknown), Francesco Galimi, Michelle M. Le Beau, Ronald M. Evans, Scott C. Kogan	63
12	CANCER THERAPY BASED ON THE Ras PATHWAY 2005 ·Cold Spring Harbor Symposia on Quantitative Biology ·Frank McCormick, Madhu Macrae, Osamu Tetsu, Pablo Rodriguez‐Viciana, Vernon T. Phan	2
13	Homodimerization of Retinoic Acid Receptor alpha through its Fusion Partners Underlies Pathogenesis of Acute Promyelocytic Leukemia. 2004 ·Blood ·Scott C. Kogan, Vernon T. Phan, Thomas Sternsdorf, (unknown), Jastinder Sohal, (unknown), Francesco Galimi, Ronald M. Evans	1
14	Cooperation of Cytokine Signaling with Chimeric Transcription Factors in Leukemogenesis: PML-Retinoic Acid Receptor Alpha Blocks Growth Factor-Mediated Differentiation 2003 ·Molecular and Cellular Biology ·Vernon T. Phan, David Shultz, (unknown), Timothy J. Blake, Anna Brown, Thomas J. Gonda, Michelle M. Le Beau, Scott C. Kogan	9
15	Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice identify cooperating events and genetic pathways to acute promyelocytic leukemia 2003 ·Blood ·Michelle M. Le Beau, Elizabeth M. Davis, Bhumi Patel, Vernon T. Phan, Jastinder Sohal, Scott C. Kogan	44
16	A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657 2003 ·Blood ·Jastinder Sohal, Vernon T. Phan, (unknown), Elizabeth M. Davis, Bhumi Patel, Louise Kelly, Tinya J. Abrams, A O’Farrell, D. Gary Gilliland, Michelle M. Le Beau, Scott C. Kogan	84

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact